1. A pharmaceutical composition containing, as an active ingredient, an isolated population of cells in suspension obtained from germinal lung tissue, said germinal lung tissue being at a developmental stage corresponding to the stage of the human lung / its tissue at a gestational stage selected from a range from 20 to 22 weeks of gestation. 2. The pharmaceutical composition of claim 1, wherein said gestational stage is from 20 to 21 weeks of gestation. The pharmaceutical composition of claim 1, wherein said gestational stage is from 21 to 22 weeks of gestation. The pharmaceutical composition of claim 1, wherein said isolated population of cells in suspension comprises a heterogeneous population of cells. The pharmaceutical composition of claim 1, wherein said isolated population of cells in suspension comprises progenitor cells. The pharmaceutical composition of claim 4, wherein said cells are characterized by expression of markers selected from the group consisting of: cytokeratin 5+ (CK5 +) expression of markers； cytokeratin 5+ (CK5 +) and cytokeratin 14+ (CK14 +) expression of markers； c-Kit + CD45- CD34- CD31- CD326- CD271- marker expression； c-Kit + CD34 + CD31 + marker expression； c-Kit + CD34 + CD326 + marker expression； CD34 + CD31 + CD14 + CD45 + marker expression； CD34 + CD31 + CD45- CD105 + marker expression； nestin + and / or bound with calcitonin gene protein + (CGRP +) marker expression； alfa smooth-muscle actin + (alpha-SMA +) and / or vimentin + marker expression. 7. The pharmaceutical composition of claim 4, wherein said cells are capable of regenerating structural / functional lung tissue or regenerating epithelial, mesenchymal and / or endothelial tissue. The pharmaceutical composition of claim 7, wherein said structural / functional tissue is l1. Фармацевтическая композиция, содержащая в качестве активного ингредиента выделенную популяцию клеток в суспензии, полученную из зародышевой легочной ткани, причем указанная зародышевая легочная ткань н
